BioSpace News Archive

Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced the presentation of four poster presentations during the Florida Society of Dermatology Physician Assistants 2022 New Wave Dermatology Conference, which will take place in Coral Gables, Fla. from April 28 - May 1, 2022.

MiNK Therapeutics, Inc. announced it will release its first quarter 2022 financial results and business update before the market opens on Tuesday, May 10, 2022.

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2022.

Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center, the Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine.

Praxis Precision Medicines, Inc. will host its 2022 Epilepsy Day live in New York City and via webcast from 8:30 to 11:30 a.m. ET.

BioCorRx Inc. today announced that it has begun the recruiting and enrollment process for its first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.

Truvian Sciences President and CEO Jeff Hawkins joins leaders of the nation’s most innovative labs to share new technologies and approaches to improve patient outcomes.

T2 Biosystems, Inc. announced today that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for the Company’s T2Biothreat™ Panel.

Vir Biotechnology, Inc. announced that the Company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH trial evaluating VIR-2218 in combination with VIR-3434, as well as a new program aimed at chronic hepatitis D. Details will be discussed at 12:00 pm ET / 9:00 am PT during Vir’s virtual Hepatitis Portfolio R&D Day.

NEOGEN Corporation (NASDAQ: NEOG) announced today that its genomics business located in Lincoln, Nebraska, has received a CLIA (Clinical Laboratory Improvement Amendments) Certificate of Compliance from the Center for Medicare & Medicaid Services (CMS).